With two FDA-cleared platforms available, the technology is drawing clinicians interested in reaping its near-term benefits while preparing for its future impact.
The center will initially use the system for prostate, and head and neck cancers and in the future will let LabCorp patients access Mount Sinai pathologists.
The spinout expects to launch its artificial intelligence- and biomarker-based monitoring tool in the third quarter of this year.
The firm plans to seek full commercial approval for its assay, which integrates biomarker identification with a patient's electronic medical record, later this year.
Epic Sciences will donate its No Cell Left Behind platform to the clinical trial, which will enroll about 1,000 patients over three years.
BGI will study pancreatic cancer with a group at Johns Hopkins and develop a diagnostic test for preterm birth detection with Mount Sinai Hospital researchers.
Coming one year after LabCorp's acquisition of Mount Sinai's Clinical Outreach business, the new partnership will standardize lab operations at seven hospitals.
Eric Schadt will serve as CEO of Sema4 and aims to move the company from genomic testing to an individualized and predictive health information firm.
The two parties are exploring opportunities to collaborate on research projects, including next-generation genomics and molecular diagnostic test development.